Inventor · disambiguated record
Frédéric Colland
Also filed as: COLLAND FREDERIC · COLLAND FRÉDÉRIC
5 granted patents·17 pending applications·34 citations·filing 2002–2022
74Inventor score
Top patents by PatentIndex Score
22 records- 0184US9546150B2Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7COLLAND FRÉDÉRIC·Filed 2012·Granted Jan 17, 2017·27 cites·23 claims
- 0279US7462615B2Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applicationsHYBRIGENICS SA·Filed 2005·Granted Dec 9, 2008·5 cites·9 claims
- 0368US7875613B2Tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applicationsHYBRIGENICS SA·Filed 2006·Granted Jan 25, 2011·1 cites·10 claims
- 0459US8648076B2Cysteine protease inhibitors and their therapeutic applicationsGUEDAT PHILIPPE·Filed 2006·Granted Feb 11, 2014·1 cites·20 claims
- 0558US2025179063A2Selective bcl-xl protac compounds and methods of useHERNER ANDRAS·Filed 2022·Application pending·0 cites
- 0658US2024376094A2Selective bcl-xl protac compounds and methods of useHERNER ANDRAS·Filed 2022·Application pending·0 cites
- 0757US2023092679A1Mcl-1 inhibitor antibody-drug conjugates and methods of useNOVARTIS AG·Filed 2020·Application pending·0 cites
- 0857US2023081720A1Mcl-1 inhibitor antibody-drug conjugates and methods of useNOVARTIS AG·Filed 2020·Application pending·0 cites
- 0953US2024269304A1Bcl-xl inhibitor antibody-drug conjugates and methods of use thereofNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1052US2024150293A1Spirocyclohexane derivatives, pharmaceutical compositions containing them and their uses as anti-apoptotic inhibitorsSERVIER LAB·Filed 2022·Application pending·0 cites
- 1151US2011237644A1Ubiquitin specific proteases responsible for mcl-1 stability and uses thereofSERVIER LAB·Filed 2009·Application pending·0 cites
- 1249US9328093B2Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applicationsHYBRIGENICS SA·Filed 2014·Granted May 3, 2016·0 cites·4 claims
- 1349US2024042051A1Mcl-1 inhibitor antibody-drug conjugates and methods of useROCCHETTI FRANCESCA·Filed 2021·Application pending·0 cites
- 1448US2022211718A1Bcl-2 inhibitors for use in the treatment of a bcl-2 mediated cancer carrying the gly101val mutationSERVIER LAB·Filed 2020·Application pending·0 cites
- 1545US2010048575A1Novel tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applicationsGUEDAT PHILIPPE·Filed 2007·Application pending·0 cites
- 1643US2022289734A13,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agentsSERVIER LAB·Filed 2020·Application pending·0 cites
- 1743US2002192796A1Anti-sigma28 factors in Helicobacter pylori, Campylobacter jejuni and Pseudomonas aeruginosa and applications thereofFiled 2002·Application pending·0 cites
- 1841US2006165699A1Use of specified tcf target genes to identify drugs for the treatment of cancer in particular colorectal cancer in which tcf/ss-cateini/wnt signalling plays a central roleCOLLAND FREDERIC·Filed 2003·Application pending·0 cites
- 1939US2013023521A1Novel selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applicationsHYBRIGENICS SA·Filed 2011·Application pending·0 cites
- 2036US2011177105A1Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic ApplicationsLOPEZ ROMAN·Filed 2010·Application pending·0 cites
- 2134US2007032499A1Novel cysteine protease inhibitors and their therapeutic applicationsGUEDAT PHILIPPE·Filed 2005·Application pending·0 cites
- 2234US2009181972A1Novel Inhibitors of Cysteine Proteases, the Pharmaceutical Compositions Thereof and their Therapeutic ApplicationsGUEDAT PHILIPPE·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Frédéric Colland files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →